Phase 1 PK study of cediranib in single and multiple doses in hepatically impaired patients with solid tumours
Study identifier:D8480C00032
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open Label Study of the Pharmacokinetics and Safety of cediranib (RECENTINTM, AZD2171) following Single and Multiple Oral Doses in Patients with Advanced Solid Tumours with Various Degrees of Hepatic Dysfunction
Medical condition
Advanced cancer, Hepatic Impairment
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2171
Sex
All
Actual Enrollment
36
Study type
Interventional
Age
18 Years - 99 Years
Date
Study Start Date: 01 Jan 2008
Primary Completion Date: 01 Jul 2010
Study Completion Date: 01 Jan 2014
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jul 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD2171 Oral dose Other Name: Cediranib |
Contacts
Investigators
Principal Investigator
CML van Herpen
Radboud University Nijmegen Medical Centre
